Two doses from either the Oxford/AstraZeneca or the Pfizer vaccine are over 80 per cent effective in preventing infection from the B1.617.2 variant of COVID-19, first discovered in India, a new UK government study has reportedly found.
1354 People wearing protective face masks wait to receive their second dose of COVISHIELD, a coronavirus disease (COVID-19) vaccine manufactured by Serum Institute of India, outside a vaccination centre in Kolkata on May 12, 2021. Reuters file photo
London, May 22
Two doses from either the Oxford/AstraZeneca or the Pfizer vaccine are over 80 per cent effective in preventing infection from the B1.617.2 variant of COVID-19, first discovered in India, a new UK government study has reportedly found.
The Oxford/AstraZeneca two-dose vaccine is also being produced by the Serum Institute of India as Covishield and being administered among the adult population in India to protect against the deadly virus.
The Oxford/AstraZeneca two-dose vaccine is also being produced by the Serum Institute of India as Covishield and being administered among the adult population in India to protect against the deadly virus
A new UK government study shows that two doses of either the AstraZeneca or Pfizer Covid vaccine provide more than 80 per cent protection against the variant first found in India.
Oxford/AstraZeneca vaccine 80% effective against B1 617 2 variant, says U K study thehindu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindu.com Daily Mail and Mail on Sunday newspapers.